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Abstract
Background: Metastases to the thyroid gland are more frequent than previously thought, although most of them
are occult or not clinically relevant. Overall, only 42 cases of metastases to thyroid from breast cancer have been
reported thus far. Here we report the case of a patient with breast cancer metastatic to the thyroid. We also review
the 42 previously reported cases (published between 1962 and 2012). This is the first review about metastases to
thyroid gland from breast cancer.
Case presentation: A 64-year-old woman of Caucasian origin was diagnosed with a lobular invasive carcinoma of
the breast (luminal A, stage II). She received adjuvant chemotherapy, followed by endocrine therapy. During follow-
up, fine-needle cytology of a thyroid nodule revealed malignant cells that were estrogen-positive, which suggested
a diagnosis of metastases to the thyroid. Imaging did not reveal any other metastatic site and showed only
enlargement of the left thyroid lobe and an inhomogeneous pattern of colloid and cystic degeneration and
calcifications. The patient underwent left hemithyroidectomy. Histology of thyroid tissue showed a colloid goitre
containing dispersed small atypical neoplastic cells with eccentric nuclei. Immunohistochemistry showed
cytokeratin-19 and oestrogen receptor, but not tireoglobulin, e-cadherin or cytokeratin-7, thereby confirming
metastases from a lobular breast carcinoma. Hormonal treatment is ongoing.
Conclusion: This case report and first review of the literature on metastases to thyroid from breast cancer highlight
the importance of a correct early diagnostic work-up in such cases. Indeed, a primary lesion should be
distinguished from metastases given the different treatment protocol related to primary cancer and the clinical
impact on prognosis.
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Background
Metastatic cancer in the thyroid is uncommon and ac-
counts for about 1.4–3% of malignant solid tumours [1–6].
The most frequent primary cancers are renal cell (48.1%),
colorectal (10.4%), lung (8.3%) and breast (7.8%) cancers,
and soft tissue sarcoma (4.0%) [1]. Large series reported
also lymphoma as primary cancer or metastases from lung
cancer other than usual epithelial thyroid cancers [7]. Also
parotid cancer and melanoma have been reported as pri-
mary cancers [8, 9]. Formerly, metastases to the thyroid
were usually identified at autopsy [9]. Thanks to the advent
of more accurate diagnostic methods, it is now possible to
clinically diagnose metastases to the thyroid, and initiate
timely surgical and systemic treatment thereby improving
outcome [2].
Case report
We report the case of a 64-year-old woman who was di-
agnosed with left breast cancer in June 2011. The co-
morbidities were multinodular goitre of the thyroid
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gland, obstructive pulmonary disease (i.e. emphy-
sema), left atrial enlargement with severe pulmonary
hypertension, carotid stenosis (60–65%) and severe
obesity. Clinical staging by chest X-ray, abdominal
ultrasound and bone scan was negative, except for
CEA = 10.7 (normal value < 5). The patient under-
went wide excision of the breast lesion with axillary
node dissection. Histology revealed a G2 invasive
lobular carcinoma with lymph node metastasis, stage
pT1cN3 (21/24 nodes), with positive staining for
oestrogen receptor (ER 90%) and progesterone recep-
tor (PgR 80%), a very low proliferation index (Ki67 <
10%), and without amplification of HER2-neu, sug-
gesting a luminal A phenotype. Adjuvant chemother-
apy with docetaxel and cyclofosfamide was
administered, followed by endocrine therapy with
aromatase inhibitor. At the first follow-up, clinical
examination showed enlarged thyroid lobes with a
multinodular structure; a thyroid function test was
normal. Ultrasound revealed an enlarged thyroid with
retrosternal development; the glandular structure was
finely inhomogeneous in the right lobe, and the en-
tire left lobe was occupied by a large nodule that
had a mixed echo-pattern and areas of cystic and
colloid degeneration and calcifications.
Fine needle cytology was performed with a 23-G
needle without suction. Smears taken from both lobes
were Diff-Quik-stained and evaluated on-site. Cellu-
larity was deemed to be satisfactory, and additional
smears were taken and alcohol-fixed for Papanicolaou
stain and for ancillary techniques. The right lobe
smear was moderately cellular and showed only col-
loid and benign thyrocytes. Conversely, the left lobe
smears revealed a second cellular population in a col-
loidal background mixed with small groups of benign
thyrocytes (Fig. 1A). This second population was con-
stituted by small cells, dispersed or aggregated into
small, loosely formed groups; individual cells had a
plasmacytoid-like aspect (Fig. 1A, inset) and occasion-
ally a secretion vacuole. Given the patient’s history,
we decided to use two smears fixed in alcohol to
evaluate oestrogen receptor expression in the second
cell population. Immunocytochemistry revealed posi-
tive oestrogen receptor staining (Fig. 1B), which sug-
gested a diagnosis of metastases of the breast cancer
to the thyroid. Positron emission tomography and
total body tomography did not reveal other metastatic
sites, and showed only enlargement of the left thyroid
lobe and an inhomogeneous pattern of colloid and
cystic degeneration and calcifications. Therefore, the
patient underwent left hemithyroidectomy in February
2012. Histology revealed thyroid tissue with a colloid
goitre containing dispersed neoplastic cells constituted
by small atypical cells with eccentric nuclei (Fig. 1C).
Immunohistochemistry revealed cytokeratin-19 and
oestrogen receptor (Fig. 2 a, b), but not tireoglobulin,
e-cadherin or cytokeratin-7, thereby suggesting metas-
tases from a lobular breast carcinoma. Thirty-two
months after hemithyroidectomy, the patient is alive,
although in May 2014, there was evidence of recur-
rence in bone. Hormonal treatment with fulvestrant is
ongoing. She died in July 2015.
Fig. 1 a Cytology of thyroid metastases and plasmacytoid-like aspect
(inset). b Immunocytochemistry with positive estrogen receptor
staining. c Histology of thyroid metastases
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Discussion and conclusions
Methods of review
We searched PubMed to identify studies about metasta-
ses to thyroid from different primary tumours, including
breast cancer. Searches were made using the terms
‘breast cancer’ and ‘metastases to thyroid’, with no limita-
tion of language, publication date, or journal of publica-
tion. Eighteen articles were eligible according to our
criteria; these were published between 1962 and 2012.
Given the rarity of metastases to the thyroid and the
limited number of reported cases, we performed only a
descriptive analysis.
Epidemiology
Metastases to the thyroid gland are rare, but not as
rare as previously thought. This is not surprising be-
cause the thyroid gland is the second most richly
arterialized organ in the body. The probability of
finding metastases in the thyroid gland depends on
the method of investigation [3]. Large autopsy studies
found that the incidence of thyroid metastases in pa-
tients with a history of cancer ranges from 1.9% to 24%
[1, 3, 8, 9]. Two of these studies suggested that thyroid
metastases are more common than primary thyroid can-
cer [1, 3]. On the other hand, the incidence of thyroid me-
tastases in clinical and surgical series was 3% [4]. Reports
of thyroid metastases have increased in recent years con-
sequent to more sophisticated diagnostic methods, i.e. fine
needle cytology and proton emission tomography with
18F–fluorodeoxyglucose [1, 10].
In autopsy series, breast cancer, lung cancer and mel-
anoma were found to be the most frequent malignancies
to metastasize to the thyroid [11]. Clinical and surgical
series of patients showed that breast carcinoma is the
second most common primary tumour to result in
symptomatic thyroid metastases, the first being clear cell
renal cancer [5, 11, 12].
Clinical and pathological presentation
The characteristics of breast cancer patients with thyroid
metastases are reported in Table 1. We analyzed sex, age
at diagnosis, histology, primary treatment, treatment fail-
ure, time between primary diagnosis and thyroid metas-
tases and follow-up in 42 women with thyroid
metastases from breast cancer reported between 1962
and 2012 [1–20]. The development of metastases of the
thyroid gland does not appear to be age-dependent, and
seems to be more frequent in women [1]. The median
age at diagnosis of metastases to the thyroid gland is
51 years (range: 22–83 years) [9, 12]. Time-to-detection
and time from presentation to death differ among re-
ports. The former ranges from 2 months to more than
15 years after the diagnosis of the primary cancer [3, 5],
and the latter from 1 to 34 months [13]. In one case,
thyroid metastases were synchronous to primary breast
cancer [10].
As shown in Table 1, the clinical presentation of
thyroid metastases is very heterogeneous. They are
clinically evident only in a minority of patients and
are frequently found incidentally during postoperative
follow-up by ultrasonography. Thyroid metastases
usually present in the context of widespread meta-
static disease, and manifestations in the thyroid are
not clinically significant. On the other hand, when
thyroid metastases are the first presentation of recur-
rent disease, they usually appear as a palpable neck
mass or, albeit less often, with dysphagia, massive tra-
cheal involvement or dysphonia. Often, patient pre-
sented with painless neck mass [21].
In the reports containing histological information,
breast cancer is generically referred to as “adenocarcin-
oma” [3, 14, 15]. Where indicated, the most prevalent
breast cancer is ductal infiltrating carcinoma [6, 8, 10],
reported in seven cases, while invasive lobular carcinoma
was reported in only our case and in a case described by
Egana et al. [12]. Not all the studies reviewed reported
the site of recurrence. In six cases. The thyroid was the
first and only site of recurrence [2–4, 6, 13]. As shown
in Table 1, other sites of widespread disease were lung,
liver and bone. In eleven cases, breast cancers recurred
in different sites, but the metastatic site other than thy-
roid was not reported [5, 14, 16].
Fig. 2 Immunohistochemistry showing cytokeratin 19 (a) and estrogen receptor (b)
Pensabene et al. BMC Cancer  (2018) 18:146 Page 3 of 8
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
br
ea
st
ca
nc
er
pa
tie
nt
s
w
ith
m
et
as
ta
se
s
to
th
yr
oi
d
in
a
cl
in
ic
al
se
rie
s
A
ut
ho
rs
St
ud
y
yr
s
N
o
of
pt
s
Se
x
A
ge
H
is
to
lo
gy
Pr
im
ar
y
tr
ea
tm
en
t
Tr
ea
tm
en
t
fa
ilu
re
Lo
ca
lD
is
ta
nt
Ti
m
e
be
tw
ee
n
BC
di
ag
no
si
s
an
d
th
yr
oi
d
m
et
as
ta
si
s
Fo
llo
w
-u
p
Sh
im
ao
ka
K
et
al
.
19
62
[9
]
19
55
1
F
44
ca
rc
in
om
a
C
T
no
LN
,b
on
e,
liv
er
,s
ki
n,
C
N
S
5
yr
s
4
m
on
th
s
W
yc
hu
lis
A
R
et
al
.,
19
64
[1
4]
19
07
–1
96
2
3
F
38
ad
en
oc
ar
ci
no
m
a
S
no
lu
ng
,b
on
e
13
yr
s
4
yr
s.
di
ed
of
th
e
di
se
as
e
F
51
ad
en
oc
ar
ci
no
m
a
S
+
RT
Ye
s
N
R
3
yr
s
5
m
on
th
s
lo
st
to
FU
F
51
ad
en
oc
ar
ci
no
m
a
S
+
RT
N
R
N
R
Sy
nc
hr
on
ou
s
(0
m
on
th
s)
1
yr
.l
os
t
to
FU
H
ar
co
ur
t-
W
eb
st
er
JN
,1
96
5
[1
5]
2
F
56
ad
en
oc
ar
ci
no
m
a
S
no
liv
er
,b
on
e
F
50
ad
en
oc
ar
ci
no
m
a
S
Pi
lla
y
SP
et
al
.,
19
77
[2
9]
19
74
–1
97
6
2
F
58
ad
en
oc
ar
ci
no
m
a
no
ye
s
F
58
N
ak
hj
av
an
iM
K
et
al
.1
99
7
[5
]
19
85
–1
99
4
7
F
67
ad
en
oc
ar
ci
no
m
a
N
R
N
R
N
R
fro
m
2
m
on
th
s
to
22
yr
s
3
pa
tie
nt
s
<
3
m
on
th
s
4
pt
s.
3–
23
m
on
th
s
C
hu
ng
SY
et
al
.,
20
01
[1
7]
19
95
–2
00
0
6
F
49
N
R
N
o
lu
ng
,b
on
e
F
61
lu
ng
F
51
lu
ng
,b
on
e,
liv
er
F
32
lu
ng
,l
iv
er
F F
22 33
bo
ne
,p
er
ito
ne
um
lu
ng
D
e
Ri
dd
er
M
et
al
.
20
03
[1
3]
19
82
–2
00
2
1
N
R
H
T
N
o
no
0
m
on
th
s
D
ie
d
af
te
r
2
ye
ar
s
fo
r
di
ss
em
in
at
ed
di
se
as
e
Lo
o
C
K,
Bu
rc
he
tt
IJ,
20
03
[1
8]
1
F
52
ne
ur
oe
nd
oc
rin
e
ca
rc
in
om
a
H
T
N
o
bo
ne
8
yr
s
W
oo
d
K
et
al
.,
20
04
[3
]
19
85
–2
00
2
1
F
72
ad
en
oc
ar
ci
no
m
a
N
o
no
15
yr
s
36
m
on
th
s
al
iv
e
O
w
en
s
C
L
et
al
.,
20
05
[1
9]
20
05
1
F
64
N
R
N
o
sh
ou
ld
er
su
bc
ut
an
eo
us
no
du
le
,l
iv
er
5
yr
s
Ki
m
TY
et
al
.2
00
5
[1
0]
19
97
–2
00
3
5
F
36
du
ct
al
C
T
N
o
N
ec
k
LN
,l
un
g
18
m
on
th
s
6
m
on
th
s
al
iv
e
F
34
du
ct
al
C
T
lu
ng
,a
x
LN
,s
ca
l
25
m
on
th
s
17
m
on
th
s
al
iv
e
F
44
du
ct
al
C
T
N
il
37
m
on
th
s
4
m
on
th
s
al
iv
e
F
55
du
ct
al
C
T
lu
ng
,a
x
LN
,n
ec
k
68
m
on
th
s
26
m
on
th
s
al
iv
e
F
45
du
ct
al
C
T
N
ec
k
LN
,l
un
g,
bo
ne
85
m
on
th
s
8
m
on
th
s
al
iv
e
G
er
ge
s
A
S
et
al
.
20
06
[8
]
19
89
–2
00
4
1
F
45
du
ct
al
S
+
C
T
+
RT
N
o
bo
ne
63
m
on
th
s
37
m
on
th
s
al
iv
e
po
st
-t
hy
ro
id
ec
to
m
y
C
ic
ho
n
A
et
al
.,
20
06
[2
]
19
84
–2
00
3
1
F
50
S
N
o
no
10
yr
s
24
m
on
th
s
al
iv
e
Pensabene et al. BMC Cancer  (2018) 18:146 Page 4 of 8
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
br
ea
st
ca
nc
er
pa
tie
nt
s
w
ith
m
et
as
ta
se
s
to
th
yr
oi
d
in
a
cl
in
ic
al
se
rie
s
(C
on
tin
ue
d)
A
ut
ho
rs
St
ud
y
yr
s
N
o
of
pt
s
Se
x
A
ge
H
is
to
lo
gy
Pr
im
ar
y
tr
ea
tm
en
t
Tr
ea
tm
en
t
fa
ilu
re
Lo
ca
lD
is
ta
nt
Ti
m
e
be
tw
ee
n
BC
di
ag
no
si
s
an
d
th
yr
oi
d
m
et
as
ta
si
s
Fo
llo
w
-u
p
M
ol
in
a
G
ar
rid
o
M
J
et
al
.,
20
06
[1
1]
20
05
1
F
43
N
R
m
as
te
ct
om
y,
ly
m
ph
ad
en
ec
to
m
y
C
T
+
RT
N
o
lu
ng
,l
iv
er
30
m
on
th
s
1
m
on
th
Pa
pi
G
et
al
.,
20
07
[6
]
19
93
–2
00
3
5
F
du
ct
al
N
o
no
5
yr
s.
1
al
iv
e
F
N
R
F
N
R
F
N
R
F
N
R
C
al
zo
la
ri
F
et
al
.,
20
08
[4
]
19
95
–2
00
5
1
F
N
R
N
o
no
60
m
on
th
s
di
ed
of
th
e
r
di
se
as
e
Sa
be
r
A
et
al
.
20
07
[2
0]
N
R
1
F
N
R
S
+
C
T
N
R
no
60
(ra
ng
e:
13
–1
35
m
on
th
s)
Eg
añ
a
N
et
al
.,
20
12
[1
2]
20
07
1
F
83
N
R
m
as
te
ct
om
y,
ly
m
ph
ad
en
ec
to
m
y
H
T
N
o
bo
ne
,l
iv
er
an
d
pe
lv
ic
m
as
s
3
yr
s
1
m
on
th
C
ur
re
nt
re
po
rt
20
11
1
F
64
IL
C
S
+
C
T
+
RT
N
o
bo
ne
6
m
on
th
s
18
m
on
th
s
al
iv
e
F
fe
m
al
e,
CT
ch
em
ot
he
ra
py
,F
U
fo
llo
w
-u
p,
LN
no
de
s,
yr
s.
ye
ar
s,
H
T
ho
rm
on
al
tr
ea
tm
en
t,
S
su
rg
er
y,
RT
ra
di
ot
he
ra
py
,N
R
no
t
re
po
rt
ed
,I
LC
in
fil
tr
at
in
g
lo
bu
la
r
ca
rc
in
om
a,
CN
S
C
en
tr
al
N
er
vo
us
Sy
st
em
Pensabene et al. BMC Cancer  (2018) 18:146 Page 5 of 8
Diagnostic work-up
Figure 3 shows a diagnostic and therapeutic work-flow
of patients with suspected metastases to the thyroid
from breast cancer. Thyroid nodules in a patient with a
history of malignancy should be investigated particularly
if they appear many years after the primary tumour. In
fact, a malignant thyroid nodule in such patients is
much more likely to be metastatic than a new primary
tumour. Thyroid metastases cannot be differentiated
from a primary thyroid cancer based on clinical fea-
tures, therefore fine needle cytology must be included
in the diagnostic work-up, particularly given its low
morbidity and cost, and its high negative predictive
value [22–24]. Cytology generally shows abundant cel-
lularity and the cells may be typical of the original
site, especially when specific immunohistochemical
stains are used. Negative staining with anti-
thyroglobulin and anti-calcitonin antibodies would
favour a diagnosis of metastatic tumour.
When papillary and follicular carcinomas have a complex
pathological pattern, cytology alone cannot reveal the ori-
gin of the metastatic tumour. The diagnosis is particularly
difficult in case of less common primary thyroid cancers
such as small cell, giant cell and spindle cell carcinomas,
anaplastic cancer and the clear cell variant of follicular car-
cinoma. Therefore, biopsy is needed to reach a definitive
diagnosis. In all the series reported so far, the diagnosis was
confirmed cytologically and histologically [1]. Regarding
the cytological differential diagnosis, a non-cohesive cell
population and a plasmacytoid-like aspect can mimic a
medullary carcinoma of the thyroid. In medullary carcin-
oma, cytological smears are usually more cellular in a back-
ground without colloid, and frequently contain amorphous
material consistent with amyloid. Tumour cells are pre-
dominantly isolated, but clusters and rosettes may also be
seen. Cells have a plasmocytoid appearance and are uni-
form in size and shape with moderate or abundant, finely
granular cytoplasm and eccentrically placed nuclei. Many
Fig. 3 Diagnostic work-up and treatment of patient with thyroid metastases from breast cancer
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smears show large cells with nuclear megaly, and bi-
nucleated and multinucleated cells. These aspects were not
observed in our patient. Indeed, in our case, the history of
breast cancer, the absence of typical findings of papillary or
follicular carcinoma, positive staining of oestrogen and
progesterone receptors, negative staining of both thyroglo-
bin and calcitonin, and the histological pattern of the pri-
mary and metastatic tumour enabled us to establish a
diagnosis of metastases from thyroid. In particular, the fol-
lowing immunocytochemical markers were analyzed: cyto-
keratin 7, cytokeratin 19, E-cadherin, CD34, besides
estrogen and progesterone receptors.
When thyroid metastases are found, it is important to
re-evaluate the diagnosis of the primary tumour and
search for other metastatic sites. Because breast cancer
has been associated with thyroid disease and because
thyroid nodules are more frequently found in women
[25], it is important to examine the thyroid during breast
ultrasonography. Ultrasonography generally shows le-
sions with irregular shape and inhomogeneus [21]. At
computer tomography, metastases to thyroid are hypo-
dense; while they look iso-hyperintense in comparison
to the normal thyroid tissue at magnetic resonance im-
aging [21]. Thyroid examination in the work-up of pa-
tients with breast cancer and goitre or nodules can
reveal thyroid metastases in an early phase. The oncolo-
gist should consider that thyroid functional tests and
radioiodine uptake are normal in most patients [1].
Management of thyroid metastases
The treatment of thyroid metastases depends on the site
of the primary tumour, presence of other metastases and
symptoms caused by the thyroid mass. Surgery is con-
sidered the gold standard treatment for thyroid metasta-
ses. Radical treatment of an isolated metastasis to the
thyroid can be curative, and an aggressive surgical ap-
proach has been recommended especially in case of slow
growing tumours such as breast or kidney carcinomas
[3]. The extension of surgical resection does not seem to
significantly impact on survival. In fact, no significant
differences in survival were found between total thyroid-
ectomy and conservative surgery [5]. Surgical treatment
of isolated metastasis may prolong survival [5]. However,
more data are necessary regarding the best surgical ap-
proach in patients with a single thyroid metastasis [4].
Patients with single metastases to the thyroid should
be treated surgically, whereas patients with multiple me-
tastases in different organs should be treated with a hor-
monal or chemotherapeutic approach in accordance
with international advanced breast cancer guidelines for
extensive disease [26]. For patients with metastatic sites
other than thyroid, surgery is generally performed to re-
duce pressure, which causes discomfort, and to avoid
airway obstruction and skin ulceration [4].
Data concerning radiotherapy or chemotherapy for
metastatic disease are fragmentary and limited. Wychulis
et al. [14] reported that radiotherapy relieved symptoms,
and should thus be considered an option, particularly in
patients with high anaesthetic risk and a clinical condi-
tion that precludes surgery. Radioactive iodine 131I has
not been found to be effective [27].
Prognosis
Reports of thyroid metastases span over more than four
decades. It is not feasible to make a global evaluation of
the outcome of patients because of the heterogeneity of
treatments and some systemic therapies that have become
obsolete. However, numerous case reports suggest that me-
tastases to the thyroid gland are associated with a poor
prognosis [28]. Multifocal metastases seem to adversely
affect prognosis. Indeed, a significantly worst survival has
been reported in patients with multiple foci. Survival after
surgical treatment is variable with some patients succumb-
ing to metastatic disease within a few months, while others
have a long-term survival. Data on prognosis cannot be ex-
trapolated also in view of the many advances made in sys-
temic treatment and in the identification of distinctive
biological features of breast cancer from the first published
case in 1962 until now. In particular, the introduction of
taxanes as well as targeted therapies, such as trastuzumab
and pertuzumab for HER2-positive tumours and bevacizu-
mab for HER2-negative tumours, which have had an enor-
mous positive effect on outcome. There are no case
reports that describe the type of systemic treatment used,
and patients were often treated with surgery, so that out-
comes cannot be extrapolated to define the prognosis of
breast cancer with metastases to the thyroid gland.
Conclusions
In this review and case report we examine aspects of
breast cancer metastases to the thyroid going from the
diagnostic workup to the treatment. Metastases to the thy-
roid gland can present many years after treatment of a dis-
tant primary tumour; however, in a patient with a history
of malignancy, a neoplastic thyroid nodule is more likely
to be a metastasis than a new thyroid malignancy. Fine-
needle aspiration biopsy of the thyroid gland should be
performed in patients with breast cancer and a nodular
goitre, even in the absence of clinical signs of metastatic
disease. Biological features are important for treatment
decision-making. Given the availability of targeted bio-
logical therapies, i.e. transtuzumab, pertuzumab and beva-
cizumab, that modify the natural history of metastatic
breast cancer, it is no longer the time to disregard the thy-
roid metastases from breast cancer and other primary
malignancies.
The history of our patient suggested thyroid goitre and
showed no clinical feature suggestive of metastasis. Our
Pensabene et al. BMC Cancer  (2018) 18:146 Page 7 of 8
case report highlights that metastases, also such an un-
usual site as the thyroid, should be considered in pa-
tients diagnosed with breast cancer. Studies dealing with
thyroid metastases are very heterogeneous in terms of
the primary cancer, which makes it difficult to evaluate
the impact of thyroid metastases on prognosis. Most pa-
tients with thyroid metastases have widespread meta-
static disease but occasionally the thyroid may be the
only site of disease. Although therapy of metastatic ma-
lignancies is often considered to be palliative, aggressive
surgical treatment in isolated cases may be curative and
may benefit survival. This highlights the importance of
early recognition and management of thyroid metastases
in prolonging survival in some patients and in prevent-
ing the onset of life-threatening complications.
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